RxDoctor Payments Data

Susan Stanton, PA

Physician Assistant · Cleveland, OHNPI 1477837581

Payments from drug & device makers

$3,036in general payments, 2019–2025

Across 38 payments — averaging $79.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • UCB, Inc.$1K
  • SK Life Science, Inc.$553
  • Neurelis, Inc.$518
  • Jazz Pharmaceuticals Inc.$447
  • Nevro Corp.$163
  • Catalyst Pharmaceuticals, Inc.$104
  • plus $146 from 2 others

What the payments were for

  • Travel & lodging$191%
  • Food & beverage$3,01799%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,036 in reported general payments places this provider in the 90th percentile of 4,098 physician assistant providers in Ohio.

See all physician assistant providers in Ohio

Medicare billing

Part B allowed, 2024
$5,264
Medicare patients
59
Services billed
84

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FycompaPerampanel17$20,752
Keppra XrLevetiracetam11$11,951
Lamotrigine ErLamotrigine23$11,894
Lacosamide51$7,958
Oxcarbazepine35$4,390
Levetiracetam84$4,260
Clobazam21$3,405
Lamotrigine75$2,748
Zonisamide45$1,860
Divalproex Sodium12$1,399
DilantinPhenytoin Sodium Extended15$1,371
Phenobarbital15$1,082
Phenytoin Sodium Extended26$689
Topiramate15$547
Clonazepam43$413

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Eisai Inc.Fycompa$61$20,75217 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,098 physician assistant providers in Ohio.

Other physician assistant in Cleveland

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →